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Introduction of point mutations in the 5V end of the human papillomavirus type 16 (HPV-16) L1 gene specifically inactivates negative
regulatory RNA processing elements. DNA vaccination of C57Bl/6 mice with the mutated L1 gene resulted in improved immunogenicity for
both neutralizing antibodies as well as for broad cellular immune responses. Previous reports on the activation of L1 by codon optimization
may be explained by inactivation of the regulatory RNA elements. The modified HPV-16 L1 DNA that induced anti-HPV-16 immunity may
be seen as a complementary approach to protein subunit immunization against papillomavirus.
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Introduction models (Jarrett et al., 1990; Lowy and Frazer, 2003; Ohlschl-Each year, about a quarter of a million women die in
cervical cancer (Ho et al., 1998; Parkin et al., 2001).
Approximately half of these malignancies are caused by
human papillomavirus (HPV) type 16. Eighty percent of all
cervical cancers occur in developing countries (Ferlay and
Bray, 2000). Many efforts are being made to prevent cervical
cancer by vaccination against HPV. The HPV-16 major
capsid protein L1 has the intrinsic capacity to self-assemble
into virus-like particles (VLPs) (Kirnbauer et al., 1992).
VLPs, but also the L1 protein in the form of capsomers,
are capable of inducing neutralizing antibodies and cellular
immunity leading to prevention of infection in animal0042-6822/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2004.02.002
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responses are induced by VLPs in clinical vaccine trials,
and a strong protective effect against persistent HPV infec-
tion has been demonstrated (Harro et al., 2001; Koutsky et
al., 2002; Pinto et al., 2003). DNA immunization is a low-
cost vaccination strategy that might permit a broadening of
the cellular responses (Tobery et al., 2003). A DNA prime or
boost immunization (Donnelly et al., 1996) strategy against
HPV-16 infection may therefore be useful in combination
with (or complementary to) protein immunization (Donnelly
et al., 1996). A problem associated with the use of HPV-16
L1 and L2 DNA is the presence of inhibitory RNA elements
within the first 514 coding nucleotides (Schwartz, 1998,
2000). The inhibitory elements efficiently reduce L1 expres-
sion to levels below detection in mammalian cells. We have
previously mapped these elements and inactivated them by
the introduction of point mutations at the DNA level, leading
to efficient viral messenger RNA processing, without affect-
ing the L1 protein sequence (Collier et al., 2002; Tan et al.,
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duction of high levels of HPV-16 L1 protein in vitro.
The present study sought to investigate whether mutant
plasmids with intrinsic capability of high-level HPV-16 L1
expression are also better immunogens in experimental
animals. Indeed, we found that the key modifications of
the L1 gene resulted in induction of high titers of neutral-
izing antibodies and broad cellular immunity in mice,
whereas the wild-type L1 gene failed to induce comparable
humoral immune responses and induced only weak cellular
responses.Fig. 1. Introduction of point mutations into the HPV-16 L1 gene results in
inactivation of inhibitory RNA elements and efficient protein expression.
(A) Three mammalian expression plasmids encoding the HPV-16 L1 gene
under control of the CMV promotor (black box) followed by the HPV-16
late polyA signal (AAA). Plasmid pCL1wt contains the wild-type HPV-16
L1 gene, pCL1MUT contains point mutations in the first 514 nucleotides of
the L1 (striped section) (Collier et al., 2002). These mutations did not alter
the amino acid sequence of the protein. Plasmid pCL1MUTDP contains
two additional point mutations that inactivate (X) the intragenic L1 polyA
signal (pA). (B) The wild-type sequence with the cryptic intragenic polyA
signal at positions 570 and 573 in the L1 coding sequence and the
mutations (underlined) in pCL1MUTDP. (C) Western blot from HeLa cells
transfected with 1 Ag of the indicated plasmids.Results
Modification of HPV-16 L1 expression plasmids
The wild-type HPV-16 L1 gene (pCL1wt) contains
sequences that inhibit protein expression by acting on the
viral messenger RNA level (Collier et al., 2002). We have
also shown that introduction of silent mutations within the
first 514 nucleotides alter inhibitory RNA elements of the
wild-type L1 and lead to expression of high levels of L1
protein. However, the L1 gene also contains a cryptic
polyA signal starting at position 570 that reduces L1
protein production as a result of premature polyadenylation
within the L1 coding sequence (O¨berg et al., 2003). To
prevent premature polyadenylation, the polyA signal was
altered by the introduction of two nucleotide substitutions
in the pCL1MUT expression vector resulting in plasmid
pCL1MUTDP (Figs. 1A, B). In vitro expression in mam-
malian cells revealed that higher levels of L1 protein were
produced when the inhibitory RNA elements were re-
moved, with even further increase of expression when
the cryptic polyA signal was altered (Fig. 1C).
The modified HPV-16 L1 gene induces binding antibodies
All animals immunized intramuscularly with 100 Ag of
either of the two modified genes, pCL1MUT or
pCL1MUTDP, responded with anti-VLP L1-specific IgG
(Fig. 2). The mean IgG titer from animals immunized with
pCL1MUT was 4400 after the second immunization and
3300 at the end of the experiment. The pCL1MUTDP
animals responded with a mean anti-VLP endpoint titer of
2100 after the second immunization and with a titer of
2300 after the third immunization. Sera from animals that
received plasmid pCL1wt, which contains the wild-type L1
gene or the empty vector pKCMV, were all negative (titers
< 10) (Fig. 2). Seven out of ten mice immunized with a
mixture of the three L1 plasmids by gene gun responded
with HPV-16 L1-specific antibodies with final titers rang-
ing from 10 to 10000 with a mean titer of 1900 (Fig. 2).
Two immunizations by the intramuscular route were need-
ed for seroconversion, whereas three immunizations were
necessary to elicit a response in gene gun-immunizedanimals. Untreated animals were negative as expected.
The ELISA was performed twice and the results were
reproducible.
Virus-neutralizing antibodies induced by modified HPV-16
L1 genes
Next we wished to determine if the antibodies would
neutralize HPV-16 virus infection. A newly developed pseu-
dovirus neutralization assay was used. Neutralizing anti-
bodies of variable titers were detected in all mice with
binding antibodies (Fig. 2). Mice that received the
pCL1MUT plasmid displayed a group mean neutralizing titer
of 1700 at the end of the experiment, whereas mice that
received plasmid pCL1MUTDP showed a group mean neu-
tralizing titer of 4300. The titers of the neutralizing antibodies
closely mirrored the ELISA capsid binding antibody titers
(r = 0.81, P < 0.05). Animals that received modified L1
plasmid DNA by gene gun immunization also showed strong
correlation between the titers of capsid-specific binding and
neutralizing antibodies (r = 0.82, P < 0.05). In this case, 5 out
of 10 animals produced neutralizing antibodies with neutral-
izing titers ranging from 150 to 3750 (Fig. 2).
Fig. 3. Helper CD4+ T cell responses measured after re-stimulation with
recombinant L1 protein. IFN-g spot-forming cells (SFC) per million
splenocytes after L1 protein stimulation (x). The cut-off () is calculated
based on pKCMV-immunized animals from intramuscular and gene gun-
immunized animals, respectively. g.g. = Gene gun immunization. i.m. =
Intramuscular immunization.
Fig. 2. Humoral immunity induced by modified HPV-16 L1 DNA. IgG
antibody titers against VLP L1 (n) and neutralizing antibody titers (5) are
compared in animals given three intramuscular immunizations. Each
individual is represented by two boxes (n and5) located above/below each
other. The horizontal order of individual mice is the same in this figure and
Figs. 3 and 4. g.g. = Gene gun immunization. i.m. = Intramuscular
immunization.
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DNA immunization is known to induce cellular immune
responses. Such responses were studied by restimulation of
spleen cells with three types of antigen: recombinant L1
protein, VLP L1, or L1 peptides followed by detection of
IFN-g. Restimulation with recombinant protein is generally
believed to stimulate the CD4+ T cell subpopulation to
secrete cytokines. Spleen cells from 8 out of 10 animals that
received plasmids pCL1MUT or pCL1MUTDP responded
322 (2004) 182–189Fig. 4. Cellular CD8+ T cell responses, measured by IFN-g EliSpot. (A)
VLP restimulation of total mouse splenocytes (n) or the same individual
after CD8+ T cell depletion (5) located above/below each other. The cut-off
for splenocytes (—) and CD8+ T cell-depleted splenocytes (---) are
calculated based on pKCMV-immunized animals from intramuscular and
gene gun immunized animals, respectively. (B) Mapping of the CD8+ T cell
response by peptide re-stimulation. L1 peptide stimulation using subdivided
L1 peptide pools covering the N-terminal (amino acids 22–175, white),
central (amino acids 170–325), and C-terminal (amino acids 321–505,
black) part of the protein. Responders above cut-off are indicated with a star
(1). g.g. = Gene gun immunization. i.m. = Intramuscular immunization.
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immunized with the wild-type HPV-16 L1 also responded
(3/5 mice), suggesting induced L1-specific CD4+ T cells. In
comparison, gene gun immunization resulted in CD4+ T cell
responses among 3 out of 10 animals (Fig. 3).
The virion–cell interaction in vivo was mimicked by
restimulation with VLPs. Stimulation of total spleen cells
from each individual animal was compared to spleen cells
depleted of CD8+ T cells from the same individual. The
results show that 5/10 animals immunized with either
pCL1MUT or pCL1MUTDP produce IFN-g after VLP
restimulation (Fig. 4A). Four out of the five responding
animals produced lower levels of IFN-g after the CD8+ T
cell population was depleted. Group means of 70 and 105
IFN-g SFCs for animals given pCL1MUT and pC-
L1MUTDP, respectively, were decreased to 36 and 56
IFN-g SFCs in the CD8-depleted splenocyte populations
(P < 0.05). None of the animals immunized with wild-type
L1 DNA and restimulated with VLPs responded above cut-
off (Fig. 4A). One out of ten gene gun-immunized animals
responded with IFN-g after in vitro VLP re-stimulation (Fig.
4A). Mapping T cells with L1 peptide pools divided into
three different parts (N-terminal, central, and C-terminal)
resulted in responses to all pools in one animal receiving
pCL1MUT (Fig. 4B). In the group receiving pCL1MUTDP,
several animals responded to more than one peptide pool.
Among the gene gun-immunized animals, the one individ-
ual that responded to VLP re-stimulation also responded to
two of three peptide pools (Figs. 3 and 4B). Overall, it was
mostly the same individuals that responded against the four
different antigens used for CD8+ T cell re-stimulation (Fig.
4). Restimulation with a control peptide library composed of
HPV-16 L2 peptides gave no responses.
In animals immunized with pCL1MUT or pCL1MUTDP
by the intramuscular route, the IFN-g responses induced
after restimulation with VLP also correlated to responses
after recombinant L1 protein (r = 0.86, P < 0.05) and L1
peptide pool (r = 0.89, P < 0.05) restimulation. There was
also a significant, but weaker, correlation between presence
of neutralizing antibodies and IFN-g production after VLP
stimulation, both with (r = 0.71, P < 0.05) or without (r =
0.79, P < 0.05) CD8+ T cells.Discussion
Our results demonstrate the importance of deleting reg-
ulatory elements that inhibit HPV-16 late gene expression in
cells other than terminally differentiated keratinocytes to
obtain appropriate immune responses by HPV-16 L1 DNA
vaccination. It is noteworthy that previous reports on an
activation of L1 expression by codon optimization (Leder et
al., 2001; Liu et al., 2001) are readily explained by a
simultaneous inactivation of regulatory RNA elements in
L1 (Collier et al., 2002; Schwartz, 1998, 2000; Tan et al.,
1995).Responses to the wild-type HPV-16 L1 gene (pCL1wt)
were compared to both a modified L1 gene where the
inhibitory element within the 514 first nucleotides (Collier
et al., 2002) was destroyed (pCL1MUT) and a modified
plasmid where, in addition, the cryptic polyA signal was
removed (pCL1MUTDP) (O¨berg et al., 2003). We noted
total absence of antibody responses in animals immunized
by wild-type HPV-16, whereas all animals immunized with
intramuscular injections with the modified HPV-16 L1
plasmids produced specific antibodies. The additional im-
provement in L1 protein expression by removing the cryptic
polyA signal (pCL1MUTDP) did not further increase the
humoral or cellular immunogenicity compared to the
pCL1MUT. End-point ELISA titers induced by our modi-
fied L1 DNA are substantially higher than reported titers
using wild-type L1 DNA vaccination regimens (Donnelly et
al., 1996; Dupuy et al., 1999) and are comparable to results
obtained by immunizing mice with the human codon
optimized HPV-16 (Leder et al., 2001) or HPV6b (Liu et
al., 2001) L1 genes. It should be noted that Leder et al.
(2001) used the potent adjuvant cardiotoxin (Martin Mu¨ller,
personal communication) while we used pegylated GM-
CSF as adjuvant. As the gene construct, the adjuvant and the
experimental conditions differed, it is difficult to compare
the outcome of the studies. In some of the animals immu-
nized with modified L1 genes, antibody titers were in the
same range as after oral or nasal immunization with HPV-16
VLPs (Dupuy et al., 1999; Gerber et al., 2001). A functional
explanation to the humoral responses induced by our
modified L1 genes is the already demonstrated direct
correlation between increased antigen expression in vivo
and enhanced antibody production (Barry and Johnston,
1997). Further, because it is well established that the
neutralizing antibodies induced by L1 are primarily type-
specific (Schiller and Lowy, 2001), with titers of cross-
reactive antibodies typically being several logarithms lower,
a detailed analysis of the cross-reactive immunity did not
appear to be a high priority analysis.
Being able to deliver an HPV vaccine by gene gun is of
clinical interest because mucosal immunity is highly desir-
able (Asakura et al., 1997; Rocha-Zavaleta et al., 2003).
Direct comparison between intramuscular and gene gun
immunization is difficult because the two methods induce
quite different immunities; thus, different doses must be
given (Han et al., 2000). In our animals, the first detectable
humoral responses were seen after the second immunization
by the intramuscular route (titers over 2000), whereas three
gene gun immunizations were needed to elicit a response
(group mean titer of 1900). Previous comparisons between
gene gun and intramuscular immunizations suggest that
both routes induce humoral immune responses (Asakura et
al., 1999; Feltquate et al., 1997). The humoral immunity
induced by gene gun immunization in our mice is due to the
modified plasmids because pCL1wt evidently is a poor
immunogen. To induce cellular immunity by gene gun
immunization has been reported difficult (Asakura et al.,
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this study. Another explanation to the overall weak cellular
immunity induced by L1 DNA gene gun immunization
compared to intramuscular immunization could be that
Langerhans cells do not easily present papillomavirus L1
antigen (Fausch et al., 2002). We argue that the amount of
antigen expressed in vivo after gene gun immunization is
enough for antibody induction but not for cellular immunity
to occur.
In previous studies, we immunized mice intranasally or
intramuscularly with 100 Ag of the modified HPV-16 L1
plasmid (pCL1MUT) without adjuvant, which did not result
in either humoral or cellular responses (data not shown).
Therefore, apparently, the adjuvant used in this study was
necessary for induction of neutralizing antibodies. A similar
enhancement of the capability to induce humoral responses
using GM-CSF as adjuvant for plasmid DNAvaccination has
been obtained in the HIV-1 gp160 surface antigen system
(Rollman, in manuscript) or together with a plasmid encoding
the HPV E6-gene (Leachman et al., 2000). Topical treatment
with Imiquimod (Kjerrstro¨m et al., in press, Vaccine) has also
been shown to enhance DNA plasmid immunization.
The overall rationale behind genetic immunization is the
advantageous intrinsic properties of DNA immunogens com-
pared to subunit antigens. Helper Tcell responses (CD4+) are
thought to be important in wart regression as well as in
clearing HPV infection (Coleman et al., 1994). This was
demonstrated in immunocompromised individuals, such as
HIV/AIDS patients, who have a high prevalence of HPV
infections (Garland, 2002). The most convincing evidence
that CD8+ T cells are important in the control/clearance of
HPV-infected cells comes from tumor challenge experiments
in mice demonstrating that if VLP-induced CD8+ T cells are
removed in vivo, the animal fails to control tumor growth (De
Bruijn et al., 1998). HPV-16 L1-specific CD8+ T cell
responses have been detected in the cervix as well as in
peripheral blood of HPV-16-infected women (Passmore et
al., 2002; Steele et al., 2002). Functional HPV-16 E6-specific
cytotoxic T lymphocyte (CTL) responses have also been
demonstrated in patients (Nakagawa et al., 2000). Further, a
recent clinical phase II trial on the cellular immunity induced
byVLPs showed induction of both CD4+ and CD8+ cytokine
producing T cells (Pinto et al., 2003).
The modified L1 DNA immunogen induces different
types of cellular responses. We describe T cell epitopes
both in the N- and C-terminal parts of the antigen, as well as
in the central region of the protein. Restimulation with
recombinant L1 antigen resulted in T helper cell responses
from animals given pCL1MUT or pCL1MUTDP as well as
from animals given the wild-type pCL1wt plasmid. Immu-
nizing mice with modified HPV-16 L1 plasmids gave rise to
IFN-g responses to HPV VLP of the total splenocytic
population and to a significantly lower degree in a CD8+
depleted subset. This demonstrates that immunization with
both modified L1 DNA plasmids induced CD4+ and CD8+
T cell responses as well as neutralizing antibodies.In summary, vaccination with HPV-16 L1 gene con-
structs modified to eliminate negative regulatory elements
resulted in potent induction of neutralizing antibodies and
cellular immunity.Materials and methods
Plasmids and in vitro expression
Plasmids pCL1wt and pCL1MUT have been described
previously as pC16L1 and pC16L1MUT#123, respectively
(Collier et al., 2002). In brief, plasmid pCL1wt encodes
nucleotides 1–1518 of the HPV-16 L1 gene under CMV
promotor control (Seedorf et al., 1985). Plasmid pCL1MUT
is identical to pCL1wt except for several point mutations
introduced into the 5V end of the gene (Fig. 1A). Plasmid
pCL1MUTDP is a modification of pCL1MUT where the
inhibitory cryptic polyA signal, located within the L1 coding
sequence, has been inactivated by substitution of two
nucleotides at position 570 and 573 (Fig. 1B) (O¨berg et al.,
2003). The intragenic polyA signal was modified by gener-
ating a PCR product using the pCL1MUT as a template,
spanning the site of mutagenesis by the use of oligonucle-
otide pAMUT (5V-GGATCCCCATGTACCAATGTTG-
CAGTAAATCCAGGTGATTGTCCACCATTAGAGTT-
GATCAACACAGTTATTCAGG-3V) together with reverse
primer L1STOP (5V-CTCGAGCTTACAGCTTAGTC-
GACCTCGAG-3V). Empty plasmid pKCMV is described
elsewhere (Ljungberg et al., 2002). All plasmids were
prepared to ensure low endotoxin levels (EndoFree Plasmid
Giga Kit, Qiagen GmbH, Hilden, Germany). In vitro cell
transfection and Western blot analyses using polyclonal anti-
L1 sera (Dillner et al., 1991) was carried out as previously
described (Collier et al., 2002). Transfection efficiency was
controlled by cotransfection of CAT expressing plasmid as
described (O¨berg et al., 2003).
Immunizations and adjuvants
Four- to eight-week-old C57Bl/6 mice were injected with
100 Ag of DNA plasmid in the quadriceps muscle. Four
groups (3–5 mice/group) received either of plasmids
pKCMV, pCL1wt, pCL1MUT, or pCL1MUTDP. In addi-
tion, a gene gun protocol (Pertmer et al., 1995) was used with
10 animals receiving 2 Ag of a plasmid mixture (pCL1wt,
pCL1MUT, and pCLMUTDP). Three animals received gold
particles coated with pKCMV. Plasmids delivered by intra-
muscular injections were adjuvanted by 5 Ag of pegylated
murine granulocyte-macrophage colony-stimulating factor
(PEG-GMCSF, Schering AG, Montville, NJ, USA) (Ljung-
berg et al., 2002). The skin of gene gun-immunized mice was
pretreated with Imiquimod (1-(2-methylpropyl)-1-H-imi-
dazo (4,5-c) quinolin-4-amine, AldaraR, 3M Pharmaceuti-
cals, France) for 5 days with particle bombardment on day 3
as described to enhance both cellular and humoral immunity
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animals was kept untreated. All immunizations were given 3
times at weeks 0, 4, and 20. Sera were obtained 10 days after
the second and third immunization.
Serology
The ELISA was essentially performed as described else-
where (Dillner et al., 1991; Kirnbauer et al., 1994). HPV-16
L1 VLPs were coated onto ELISA plates (Costar, Cam-
bridge, MA, USA) at 0.5 Ag/ml. Sera were diluted in PBS
with 10% horse sera (Sigma, St Louis, MO, USA). Bovine
papillomavirus (BPV) capsids were used as background
control antigen. HPV and BPV VLPs were obtained from
Dr. John Schiller, and the positive control anti-HPV-16
monoclonal V5 antibody was obtained from Dr. Neil Chris-
tensen. Goat-anti-mouse-HRP conjugate was used at dilution
1:2000 (Southern Biotechnology, Birmingham, USA). Plates
were developed using ABTS substrate (Roche, Mannheim,
Germany) and read at OD450 nm. An absorbance of more
than twice the BPV background absorbance was considered
positive.
Pseudovirus neutralization
The human 293T cell line stably overexpressing addition-
al SV40 large T antigen cDNA (293TT cells) was cotrans-
fected with plasmids encoding the human codon-adapted
HPV-16 L1/L2 (Leder et al., 2001), and an SV40 ori+
plasmid expressing secreted alkaline phosphatase (SEAP)
(BD-Clontech, Palo Alto, CA) (Buck et al., 2004). Pseudo-
virions were harvested after 48 h by sonication and incubated
with 100 U/ml DNaseI (Invitrogen, Carlsbad, CA) at 37 jC
for 15 min. The lysate was pelleted through a 30% sucrose
cushion at 16000  g for 1 h. Particles were resuspended in
Dulbecco’s PBS (Life Technologies, now Invitrogen) and
stored at 70 jC. Sera were diluted and mixed with the
pseudovirus for 1 h at 4 jC and transferred to 96-well plates
with 30000 293TT cells/well. Supernatants were assayed for
SEAP after 72 h using the Great EscAPe SEAP Chemilu-
minescence Detection Kit (BD-Clontech). Plates were read
by a Dynex MLX MicrotiterR Plate Luminometer to obtain
relative light unit (RLU) values. The limit of detection was
set to a titer of 10. The result is presented as the mean titer of
one to three independent assays. The pseudovirus neutrali-
zation assay is described in detail in a separate manuscript
(D.V. Pastrana et al., in press, Virology).
Spleen IFN-c EliSpot
Murine splenocytes were purified using a ficoll gradient
(Amersham Pharmacia Biotech, Uppsala, Sweden). Magnet-
ic beads (Dynal, Oslo, Norway) were used to deplete CD8+
T cells from half of the splenocytes. This CD8+ T cell
depletion was performed to determine the fraction of IFN-
g produced by this splenocyte subpopulation. Splenocyteswere distributed (600000 cells/well) in round bottom 96-
well plates (Costar) and restimulated with HPV-16 L1 virus
like particles (10 Ag/ml), L1 protein expressed in E. coli (5
Ag/ml), or synthetic peptide pools composed of 20-mer
peptides with a five-amino acid overlap representing the
L1 or L2 sequences (5 Ag/peptide/ml) (Dillner, 1990). Cell
reactivity was confirmed with concanavalin A. After 16 h at
37 jC, cells were transferred into triplicates of 200000 cells/
well in 96-well EliSpot plates (Millipore MAIPN4510, Bed-
ford, MA, USA) coated with anti-IFN-g antibodies (Diac-
lone, Besancon, France). Spot-forming cells (SFCs) were
quantified 24 h later by an AID EliSpot reader (Autoimmun
Diagnostika GmbH, Germany) and calculated as the geo-
metric mean of the antigen-stimulated cells minus unstimu-
lated cells. The cut-off for a given antigen was calculated as
the group geometric mean of control animals (pKCMV) and
two standard deviations. The efficiency of CD8+ T cell
depletion was confirmed by flow cytometry. Total and
CD8+ depleted splenocytes (106) were stained for 30 min
at 4 jC with antibodies GK1.5 (anti-CD4; FITC, BD
Pharmingen) and 53–6.7 (anti-CD8a; PerCP, BD Pharmin-
gen). On average, 92% of the CD8+T cells were removed.
Statistics
The Student’s t test for dependent samples (Statistica 6.0,
Uppsala, Sweden) was used for the analysis of spot fre-
quencies in the complete cell population in comparison to
the CD8+ T cell depleted population. Pearson correlation
coefficient was used to estimate correlation between anti-
body titers, neutralization titers, and spot frequencies. The
criteria for statistical significance was P < 0.05.Acknowledgments
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